医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Groupe Athena, Inc. Welcomes New Director, Announces Intent to Apply for UK License

2013年09月05日 PM10:40
このエントリーをはてなブックマークに追加


 

MUMBAI, India

Groupe Athena, Inc. (OTC Pink:GATA.PK) announced today that Dr. Chitra Saxena has been elected to join their Board of Directors. Dr. Saxena is a skilled expert in UK and European regulatory requirements for prescription and non-prescription pharmaceutical drugs. During her distinguished career, she has been associated with several multinational companies including Reckitt Benckiser, Slough, UK, Bayer PLC, Newbury, UK and DDSA Pharmaceuticals Limited, Fulham, UK. She has also published 23 research papers in various internationally reputed trade journals.

In related news, Groupe Athena, under the guidance of Dr. Saxena, will commence the application process to obtain regulatory approval for licenses for the sale of certain prescription drugs within the UK and later in the European Union. The process is likely to be completed within 18-24 months. This will include plant approvals, pilot manufacturing and licensing.

Groupe Athena Chairman, D. Purohit stated, “We are very privileged to have Dr. Saxena join our board of Directors, and her knowledge of the regulatory and licensing processes within the UK and EU will prove invaluable as we transition to the manufacturing and marketing side of the pharmaceutical industry.”

The Indian pharmaceutical industry was estimated to be over $21 Billion in 2010 and is expected to experience double-digit annual growth through the end of the decade. GATA has emerged as a vital component of this growth by its ability to help Indian manufacturers get their products approved by the FDA for sales in the US.

For more information on Groupe Athena, Inc. please go to www.otcmarkets.com/stock/GATA/quote or visit our corporate website at www.groupeathena.com.

About Groupe Athena, Inc.

Groupe Athena Inc. was incorporated in June 2008 and began operations on July 1 of that year. The company is a research and testing organization and helps various pharmaceutical and medical products and devices companies in India and Southeast Asia to get regulatory approvals and facilitate exports of their products to the United States. The Company accomplishes this by assisting clients from concept through development, providing consultation on regulatory requirements, filings and processes.

The company has a research and marketing facility in India that currently employs 17 consultants and marketing personnel and is working towards aggressively expanding its presence in the Indian pharmaceutical industry. The Company’s web address is www.groupeathena.com

For more information contact:
Paul Cornell
Corporate Shareholder Relations
Cornellpaul6@gmail.com

Safe Harbor Statement
Certain statements set forth in this press release constitute “forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate”, “project”, “intend”, “forecast”, “anticipate”, “plan”, “planning”, “expect”, “believe”, “will likely”, “should”, “could”, “would”, “may” or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company’s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company’s ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company’s limited operating history, the limited financial resources, domestic or global economic conditions — activities of competitors and the presence of new or additional competition and conditions of equity markets.

CONTACT

Groupe Athena Inc.
Paul Cornell, 1-877-647-6876
Corporate
Shareholder Relations
Cornellpaul6@gmail.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing
  • 三叶草生物制药完成6,280万元人民币A轮融资
  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表